LRRC53 Inhibitors
The LRRC53 inhibitors belong to a diverse chemical class that includes compounds targeting key signaling pathways implicated in LRRC53-associated cellular processes. These inhibitors act through various mechanisms to modulate gene expression, cellular signaling, and epigenetic regulation.
Retinoic acid acts as an agonist for nuclear receptors, influencing LRRC53-related pathways through gene expression modulation. Inhibitors like PD98059, SB203580, and U0126 target MAPK/ERK signaling, affecting LRRC53-associated cellular functions by disrupting this pathway. LY294002, Wortmannin, and AZD8055 inhibit components of the PI3K/AKT/mTOR pathway, impacting LRRC53-related cell survival, growth, and metabolism.
Histone deacetylase inhibitors like Trichostatin A and JAK/STAT pathway inhibitor AG490 modify chromatin structure and disrupt JAK2-mediated signaling, respectively, influencing LRRC53-associated gene expression. SB431542 targets TGF-β signaling, influencing LRRC53-related processes like cell differentiation and migration.
SP600125 and Rapamycin modulate JNK and mTOR pathways, respectively, affecting LRRC53-related cellular processes such as stress response, apoptosis, and protein synthesis. This diverse array of LRRC53 inhibitors collectively provides valuable insights into potential targets for modulating LRRC53 function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid (RA) acts as an agonist for nuclear receptors (RARs and RXRs). Activation of these receptors by RA can modulate gene expression, influencing cellular processes related to LRRC53. The impact on gene transcription may result in regulatory effects on LRRC53-associated pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK1, a component of the MAPK/ERK pathway. Inhibition of MEK1 prevents the activation of ERK1/2, leading to downstream effects on gene expression and cellular processes. PD98059 may influence LRRC53-related pathways by modulating the MAPK/ERK signaling cascade, affecting cell proliferation and differentiation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK, a kinase involved in stress response and inflammation. Inhibition of p38 MAPK can affect downstream signaling pathways, potentially impacting LRRC53-related cellular processes. SB203580 may modulate the p38 MAPK pathway, leading to alterations in gene expression and cellular functions associated with LRRC53. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks), crucial components of the PI3K/AKT signaling pathway. Inhibition of PI3Ks can disrupt AKT activation, influencing downstream targets. LY294002 may affect LRRC53-related pathways by modulating PI3K/AKT signaling, impacting cell survival, growth, and metabolism. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase (HDAC) inhibitor, leading to increased histone acetylation and altered chromatin structure. This epigenetic modulation can influence gene expression and cellular processes. Trichostatin A may impact LRRC53-associated pathways by modifying chromatin accessibility and gene transcription, resulting in regulatory effects on LRRC53 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a specific inhibitor of PI3K, disrupting the PI3K/AKT signaling pathway. Inhibition of PI3K by Wortmannin can affect downstream signaling cascades, potentially influencing LRRC53-related cellular processes. This compound may alter PI3K-mediated regulation of cell survival, growth, and metabolism, impacting LRRC53 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, crucial components of the MAPK/ERK signaling pathway. Inhibition of MEK1/2 prevents the activation of ERK1/2, leading to downstream effects on gene expression and cellular processes. U0126 may modulate LRRC53-related pathways by disrupting MAPK/ERK signaling, influencing cell proliferation and differentiation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is a selective inhibitor of TGF-β type I receptor (ALK5), a key component of the TGF-β signaling pathway. Inhibition of ALK5 can alter downstream signaling, influencing cellular processes related to LRRC53. SB431542 may impact LRRC53-associated pathways by modulating TGF-β signaling, leading to changes in cell differentiation, migration, and survival. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $82.00 $323.00 $219.00 $85.00 | 35 | |
AG490 is a JAK2 (Janus kinase 2) inhibitor, disrupting JAK/STAT signaling. Inhibition of JAK2 by AG490 can affect downstream STAT activation, potentially influencing LRRC53-related cellular processes. This compound may alter JAK/STAT-mediated regulation of gene expression and cellular functions associated with LRRC53. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK), a kinase involved in stress response and apoptosis. Inhibition of JNK can affect downstream signaling pathways, potentially impacting LRRC53-related cellular processes. SP600125 may modulate the JNK pathway, leading to alterations in gene expression and cellular functions associated with LRRC53. | ||||||